Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Carnegie Healthcare Conference 2025
8 slides from Vitrolife Ab's conference presentation, Mar 11, 2025
Slide 1: Vitrolife AB (publ) – Carnegie Healthcare Conference
Vitrolife AB (publ) Carnegie Healthcare Conference 2025-03-11 Bronwyn Brophy O'Connor, CEO Helena Wennerström, Acting CFO
Slide 2: The sheer magnitude of the global infertility healthcare issue
The sheer magnitude of the global infertility healthcare issue Adults >20 years old Adults >20 living Adults affected Coronary artery disease with Diabetes by infertility 2 Source: CDC International Diabetes Foundation, ESHRE, SART
Slide 3: Significant market opportunity in reproductive health
Significant market opportunity in reproductive health Successful treatment outcomes ~33% *** 1 in 6 134 M Access and affordability constraining ~5% people globally is babies born annually** estimated cycle growth affected by infertility* < 1% via IVF growth in coming years *Source: World Health Organ
Slide 4: Corporate Strategy Vitrolife Group
Corporate Strategy Vitrolife Group Market Labour Growth in and skills Consoli- Regionali- Patient megatrends demand shortage dation sation Empowerment Our values Vision with a purpose Long-term growth and profit-targets (5 years) Integrity ”Enable people to fulfil the dream of having a healthy baby” A
Slide 5: Focus for 2025
Focus for 2025 Advance penetration of Embryoscope and eWitness to improve Own the platform connecting products and services workflow, automation, and traceability in IVF clinics Continue to invest in our R&D pipeline to bring new solutions Innovate to expand leadership to market faster Increase share
Slide 6: Background on PGT-A: In a nutshell
Background on PGT-A: In a nutshell What is PGT-A test? What are the Steps Required for patients to be performed PGT-A during their IVF Process? PGT-A is a genetic study of the embryo produced during IVF treatment to identify numerical chromosome aneuploidies First step is Patients visiting IVF Cli
Slide 7: Reasons to invest in Vitrolife AB (publ)
Reasons to invest in Vitrolife AB (publ) • Underlying resilient market growth. • High quality brands linked with outstanding service and support. • Proven track record of profitable growth. • Innovation and technology leader within fertility. • Ambitious strategy and long-term objectives. Contact: in
Slide 8: Disclaimer
Disclaimer This presentation may contain estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there